NASAL

PATIENT SAFETY: KEY DRIVER TO PRESERVATIVE-FREE NASAL SPRAY DEVELOPMENT

Benoît Guillard, Pascale Farjas and Audrey Chandra look at the effects of preservatives in nasal sprays, and the challenges and advantages of delivering preservative-free nasal spray drugs.

WHEN EVERY SECOND COUNTS…

Todd Pizitz and Donald Mealing look at efforts to reduce the number of opioid-related deaths in the United States, and introduce a nasal device that delivers naloxone.

THE CURRENT STATE OF PLAY IN CONNECTED DEVICES

THE CURRENT STATE OF PLAY IN CONNECTED DEVICES

Marcus Bates; Joachim Koerner and Jerôme Prraquin discuss the current state of play, what connected device advocates are doing to enable faster implementation, and how we can optimise connected technology while reducing the cost and improving human factors.

A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE

A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE

Jag Shur explores the challenges companies face in bringing generic respiratory and nasal therapies to market – and how some organisations have proactively addressed the challenge and developed services to integrate the device and the formulation, introducing the Aptar Pharma Services offering.

F2V: A STERILE, CUSTOMISABLE LIQUID FILL-FINISH PLATFORM FOR THE TOTAL LIFECYCLE

INDUSTRIALISATION

Simon Strothers

F2V: A STERILE, CUSTOMISABLE LIQUID FILL-FINISH PLATFORM FOR THE TOTAL LIFECYCLE

Simon Strothers presents an integrated fill-finish platform, F2V, designed to represent a commercial filling system as a bench-top solution. The article also includes a recent case study where the F2V was used by Consort Medical to help develop and industrialise a flagship delivery device.

CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL

CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL

Thierry Decock and Hadrien Gremillet explore how the obstacles to the adoption of connectivity can be overcome and how connected devices can deliver truly patient-centric care that will clearly improve adherence rates, whilst demonstrating a clear cost benefit to the pharmaceutical partner.

BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE

BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE

Joe Reynolds discusses the current state of pulmonary drug delivery device trainers, including their value to patients, the complexities of modern design and the stringent quality requirements.

GUILLAUME BROUET, APTAR PHARMA

Guillaume Brouet

GUILLAUME BROUET, APTAR PHARMA

Guillaume Brouet talks with ONdrugDelivery Magazine about how Aptar Pharma uses its device development expertise and infrastructure to provide its pharmaceutical company customers a comprehensive services offering around device development, global regulatory approval and commercialisation.

THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT

THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT

David Belton discusses the meaning of quality by design in novel respiratory drug delivery device development. He covers how, with more novel devices, prior knowledge may be insufficient for a standard FMEA-style risk analysis, and alternate science-based methods, such as functional mapping and knowledge scoring, can help in achieving QbD.

PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP

Consort Medical

PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP

Consort Medical's Paul Allsop, Miles Kottman, Hannah Priestly and Jon Reed talk with ONdrugDelivery Magazine about the company’s integrated formulation and device offering, and focus on its simple, low-cost, single unit-dose, spring powered nasal device, Unidose Xtra.

130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC

130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC

Todd Pizitz and Donald Mealing discuss the ongoing opioid crisis in the US and the current use of the opioid reversal medication naxalone, and introduce the CounterAct device for naxalone home use.

IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?

IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?

Igor Gonda covers the field of nasal and pulmonary delivery of biologics, considers past failures and successes, and proposes answers to the challenges faced, from biological, biopharmaceutical and commercial standpoints.

BK814 The Unidose™ Xtra nasal spray device: designed for simplicity

Consort Medical

BK814 The Unidose™ Xtra nasal spray device: designed for simplicity

In this Video Consort Medical's Bespak division introduces its single dose Unidose™ Xtra nasal spray device offers unique performance advantages through the use of IP-protected mechanisms that control device actuation and aqueous drug delivery.

REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION

Proveris Scientific

REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION

Heli Chauhan and Linda (Lingzhi) Liao discuss the importance of automated actuation for testing inhalation and spray devices to avoid variability introduced by manual method.

NASAL DRUG DELIVERY VIA THE ORAL ROUTE USING A PMDI

Dr Laurent Vecellio

University of Tours

NASAL DRUG DELIVERY VIA THE ORAL ROUTE USING A PMDI

Laurent Vecellio, Déborah Le Pennec and Alain Regard, Technology Product Manage discuss a study Nemera has funded into the retronose concept, using a pMDI to deliver to the nasal cavity via the oral route during exhalation through the nose.

EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY

EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY

Nemera introduces the e-Novelia® and e-Advancia® add-ons for ophthalmic and nasal devices.

DRUG REPURPOSING – BROADENING PATIENT ACCESSIBILITY VIA A CHANGE IN DRUG DELIVERY SYSTEM

DRUG REPURPOSING – BROADENING PATIENT ACCESSIBILITY VIA A CHANGE IN DRUG DELIVERY SYSTEM

Badre Hammond, Gerallt Williams and Herve Pacaud discuss the growing trend of drug repurposing.

INFLUENCE OF THE HUMAN FACTOR ON NASAL DRUG DELIVERY DEVICE EVALUATION

INFLUENCE OF THE HUMAN FACTOR ON NASAL DRUG DELIVERY DEVICE EVALUATION

Pascale Farjas, Alain Regard and Guillaume Grevin, discuss what is required of a modern nasal spray pump and how introducing the human factor showed a significant impact on the variability of delivered volume.

ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE

Proveris Scientific

ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE

Heli Chauhan details the myriad challenges facing the OINDP market, with a particular emphasis on nasal spray devices, when it comes to testing products on a mass-production scale, such as a lack of adequate testing equipment and the need to capture accurate data consistently. She goes on to offer a solution in the form of Indizo®, Proveris’ automated nasal spray testing apparatus.

THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY

THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY

Pascale Farjas, Alain Regard, and Céline Petitcolas discuss the steps taken when designing a nasal spray device for the growing bioequivalence market and the key competencies, including experience with regulations and regulatory agencies in numerous geographic regions, that Nemera can offer throughout the process.

INNOVATIVE NASAL APPLICATION REQUIRES INNOVATIVE FILLING TECHNOLOGY

Dr Karlheinz Seyfang

INNOVATIVE NASAL APPLICATION REQUIRES INNOVATIVE FILLING TECHNOLOGY

Karlheinz Seyfang discusses the development of a system for the nasal delivery of a thixotropic gel formulation, from the design of the system through to the production line.

CONTROLLED-RELEASE SYSTEMS FOR PROTEINS & PEPTIDES

Dr S Mohan Mohanraj

CONTROLLED-RELEASE SYSTEMS FOR PROTEINS & PEPTIDES

S Mohan Mohanraj and Meier Kende discuss development of a viable intranasal microsphere-based delivery system and how it delivers a recombinant anthrax vaccine via two-dose immunisation.

A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY

A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY

Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. Pascale Farjas, provides an overview of an innovative nasal delivery system, Advancia®, a true platform.

BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE

BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE

Pascale Farjas describes the company’s Device Equivalence Program, which enables Nemera to preselect and propose an appropriate delivery system per identified drug to companies wishing to save time in their nasal spray development pipeline.

SONIC NEBULISATION IN RHINOLOGY

Dr Laurent Vecellio

SONIC NEBULISATION IN RHINOLOGY

Laurent Vecellio, Sandrine Le Guellec and Gilles Chantrel describe a sonic nasal nebuliser that operates with an acoustic frequency of 100Hz, and clinical studies demonstrating its efficacy in the delivery of treatments for CRS.

SCOPING THE DESIGN SPACE FOR GENERIC NASAL SPRAYS

Dr Deborah Huck-Jones

Malvern Panalytical

SCOPING THE DESIGN SPACE FOR GENERIC NASAL SPRAYS

Deborah Huck-Jones and Paul Kippax discuss analytical methods that can be helpful for demonstrating bioequivalence in the development of generic nasal sprays.

1
2
Next

Top

W3 Total Cache is currently running in Pro version Development mode.